Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 STROBE Study of TNX-1900 for the Treatment of Binge-Eating Disorder - Marketscreener.com
| RASP Stock | USD 0 0.00 0.00% |
Slightly above 56% of Rasna Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Rasna Therapeutics pink sheet suggests that many investors are alarmed at this time. Rasna Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Rasna Therapeutics. Many technical investors use Rasna Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Rasna |
Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 STROBE Study of TNX-1900 for the Treatment of Binge-Eating Disorder Marketscreener.com
Read at news.google.com
 |
Rasna Therapeutics Fundamental Analysis
We analyze Rasna Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rasna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rasna Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Rasna Therapeutics is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Rasna Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rasna Therapeutics pink sheet to make a market-neutral strategy. Peer analysis of Rasna Therapeutics could also be used in its relative valuation, which is a method of valuing Rasna Therapeutics by comparing valuation metrics with similar companies.
Peers
Rasna Therapeutics Related Equities
| BNOX | Bionomics | 7.14 | ||||
| VTYX | Ventyx Biosciences | 1.13 | ||||
| PCVX | Vaxcyte | 0.38 | ||||
| ACUT | Accustem Sciences | 0.00 | ||||
| IMCR | Immunocore Holdings | 0.27 | ||||
| SABS | SAB Biotherapeutics | 1.02 | ||||
| ACLX | Arcellx | 1.12 | ||||
| IGC | India Globalization | 2.63 | ||||
| GHRS | GH Research | 3.77 | ||||
| SPRC | Scisparc | 4.55 |
Additional Tools for Rasna Pink Sheet Analysis
When running Rasna Therapeutics' price analysis, check to measure Rasna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rasna Therapeutics is operating at the current time. Most of Rasna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rasna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rasna Therapeutics' price. Additionally, you may evaluate how the addition of Rasna Therapeutics to your portfolios can decrease your overall portfolio volatility.